The Latest Biology News And Medical NewsBiology News 2Health News 2Biology News 3Health News 3
HOME >> MEDICINE >> NEWS
Small Risk Of Pill Disappears After Ten Years

(Mortality associated with oral contraceptive use: 25 year follow up of cohort of 46,000 women from Royal College of General Practitioners' oral contraception study)

Click below to download PDF document
You will require Acrobat Reader to view file.
Click here for PDF document

More than 300 million women throughout the world have used oral contraceptives since their inception in 1959. Although the short term effects of the pill are well documented, less is known about the long term effects. In this week's BMJ, Professor Valerie Beral and colleagues from the Imperial Cancer Research Fund and the Royal College of General Practitioners report the results of a 25 year follow up of 46,000 women in the Royal College of General Practitioners' oral contraceptive study.

They found that women who had stopped using the pill for ten or more years incurred no more health risks than women who had never used the pill. They conclude that the small risks of using oral contraceptives are relevant only while they are being used and in the ten years after use ceases. After this time period there is little evidence to suggest any persistent adverse effects.

Contact:

Geoff Watts or Bryher Golding-Barrett at Imperial Cancer Research Fund, Communications Department

t: +44 171 269 3613

f: +44 171 269 3262
g.watts@icrf.icnet.uk

or b.golding-barrett@icrf.icnet


'"/>

Contact: Jill Shepherd
jshepherd@bma.org.uk
44-171-383-6529
BMJ-British Medical Journal
8-Jan-1999


Page: 1

Related medicine news :

1. Small increases or blips in HIV levels do not signal mutations leading to drug-resistant HIV
2. Rices CNST awards Smalley/Curl funds for innovation
3. Small steps toward coverage
4. Small band of nurses plays key role keeping germ threats at bay
5. Small social circles tied to heart disease death in women
6. Small study shows SAMe may improve treatment of depression
7. South Floridas Small wins The Gerontological Society of Americas 2004 Margret M. Baltes Award
8. Smallpox vaccine can be diluted and still be effective, expanding supply if needed
9. Small, frequent doses of caffeine best strategy for staying awake
10. New study: Small, frequent doses of caffeine best strategy for staying awake
11. Small uterine fibroids may be linked with increased risk of miscarriage, early study results show

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Small Risk Pill Disappears After Ten Years

(Date:11/25/2009)... New minimally-invasive pro...inus pain and decrease the risk of sinusitis, or s...e physicians of the Atlanta Snoring Institute. Te...and congested sinuses without having to remove any... The advantages of these breakthroughs in treating...
(Date:11/25/2009)...,, VANCOUVER,Nov.25/PRNewswire/-- AdamDreamHeal...ealingintentionschangesthephysiologyofsomeoneatadi...atatimeunknowntoavolunteerwhowasmonitoredbyaquanti...AandCanada. ,, OnNovember8inVancouver,B.C.Adami...ent.Tofocusintentions,Adamcreatedavideoclipofaspec...
(Date:11/24/2009)... Eating high amounts of salt is linked to a signi... disease, states a paper published today in the B...ied out jointly by the World Health Organization,s...University of Warwick and University Hospital in C...ion Excellence Centre in Hypertension based at the...
(Date:11/24/2009)...(Boston) Researchers from Boston University Schoo...medical Engineering Department have identified a n...distinguish between cancer and normal cells with a...earchers have developed a new computational strate...key biological pathways (molecular circuits) that ...
(Date:11/24/2009)...,, DALLAS,Nov.24/PRNewswire-USNewswire/--TheBay...rofoneofthelargestcancerclinicaltrialscooperativeg...heNationalCancerInstitute,SouthwestOncologyGroupco...s,andtoimprovethequalityoflifeforcancersurvivors. ...eradditional,importantclinicaltrialstocancerpatien...
Breaking Medicine News(10 mins):Health News:Atlanta Snoring Institute Uses Breakthrough Techniques to Treat Sinusitis and Sinus Pain 2Health News:Atlanta Snoring Institute Uses Breakthrough Techniques to Treat Sinusitis and Sinus Pain 3Health News:Atlanta Snoring Institute Uses Breakthrough Techniques to Treat Sinusitis and Sinus Pain 4Health News:Intriguing Scientific Results from World's Largest Intention Healing Project: DreamHealer 2Health News:High salt intake linked to strokes and cardiovascular disease 2Health News:Researchers identify proteins in lung cancer cells that may provide potential drug targets 2Health News:Baylor Sammons Cancer Center Joins One of Nation's Largest Cancer Clinical Trials Groups 2
(Date:11/24/2009)...,Nov.24/PRNewswire-FirstCall/--AnadysPharmaceutica...entatthe21stAnnualPiperJaffrayHealthcareConference....TheconferenceisbeingheldatTheNewYorkPalaceHotel.S...rofAnadys,willprovideanoverviewofAnadysanditsclini...orporatepresentationwillbesimultaneouslywebcastand...
(Date:11/24/2009)...ON,Calif.,Nov.24/PRNewswire-FirstCall/--ThoratecCo...dmechanicalcirculatorysupporttherapiestosave,suppo...ticipatinginthe21stAnnualPiperJaffrayHealthCareCon...cutivevicepresidentandchieffinancialofficer,willpr...ernStandardTime(5:30a.m.,PacificStandardTime). ,...
(Date:11/24/2009)...N.C.,Nov.24/PRNewswire/--PharmaceuticalInstitute,a...epharmaceuticalandbiotechindustry,todayannouncedth...Thenew HospitalMarketplace e-courseisthenewestaddi...ries,acomprehensiveseriesofe-coursesdesignedtofill...owledgeforcommercialprofessionals. ,, Thenewthr...
Breaking Medicine Technology:Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference 2Pharmaceutical Institute Launches New Training Resource Focused on the Hospital Marketplace 2 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 1 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 2 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 3 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 4 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 5 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 6 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 7 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 8 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 9Cardax Pharmaceuticals Nominates Clinical Candidate Heptax for Liver Disease 3B Heptax Ameliorates Inflammation and Oxidative Stress Related to Liver 4745 1Cardax Pharmaceuticals Nominates Clinical Candidate Heptax for Liver Disease 3B Heptax Ameliorates Inflammation and Oxidative Stress Related to Liver 4745 2Highlights of Economic and Business Growth in the Tampa Bay Region 28News Briefs 29 52073 1Highlights of Economic and Business Growth in the Tampa Bay Region 28News Briefs 29 52073 2Highlights of Economic and Business Growth in the Tampa Bay Region 28News Briefs 29 52073 3Highlights of Economic and Business Growth in the Tampa Bay Region 28News Briefs 29 52073 4
Other News:
...similar to AIDS treatment. . Researchers have succ...hat -- in test tube studies -- can stop the chain ...ing reported in the current (April 12) print editi..., published by the American Chemical Society, the ...
.... . . . . People with sleep apnea are at special ... by the National Heart, Lung, and Blood Institute ...a from the NHLBI's "Sleep Heart Health Study" (SHH... of the Journal of the American Medical Associatio...
............ Columbia researchers have participated in a new study that points toward a potential treatment for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.... The study, l
...spitals are contributing to health promotion and d...is significant variation in such efforts, accordin...elated hospitals and hospitals that are part of he...he largest percentages for offering services such ...
health news:Protease inhibitor could help prevent alzheimer's 2health news:NHLBI study shows relationship between sleep apnea and hypertension 2health news:Researchers identify pathway that may slow the progression of Lou Gehrig's disease 2health news:Hospitals vary in provision of wellness services 2
...updated the current guidelines for diagnosing mult...netic resonance imaging (MRI). The guidelines, pub...eurology (http://www.interscience.wiley.com/journa...ve years ago and named after the chair of the prev...
...te, they have more academic and attention problems...dical School to be published in the December issue...ensuring students get enough sleep is a significan...n class as well as minimizing behaviors characteri...
... eased the pain of millions of patients -- but it ...d stroke among some of them. And that extra risk o...of data from Vioxx research studies.......Failure ... go unnoticed but could frequently be prevented if...
People taking highly active antiretroviral therapy (HAART) for HIV infection remain susceptible to tuberculosis, though the risk is lower than for HIV-infected patients not on HAART, according to an a
health news:Neurologists refine multiple sclerosis diagnostic criteria 2health news:A good night's sleep can mean a better day at school 2health news:A good night's sleep can mean a better day at school 3health news:Preventing another Vioxx 2health news:Preventing another Vioxx 3health news:Preventing another Vioxx 4health news:Preventing another Vioxx 5health news:Tuberculosis still a risk for patients receiving HIV drugs 2